Galera Therapeutics Inc Ordinary Shares GRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GRTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.20
- Day Range
- $0.17–0.21
- 52-Week Range
- $0.09–3.59
- Bid/Ask
- $0.18 / $0.21
- Market Cap
- $10.12 Mil
- Volume/Avg
- 4.2 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
- Website
- https://www.galeratx.com
Comparables
Valuation
|
Metric
|
GRTX
|
VOR
|
LYEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.78 | 0.90 |
Price/Sales | — | — | 4,498.07 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GRTX
|
VOR
|
LYEL
|
|---|---|---|---|
Quick Ratio | 3.68 | 8.81 | 15.82 |
Current Ratio | 4.36 | 9.04 | 16.07 |
Interest Coverage | −4.32 | — | — |
Quick Ratio
GRTX
VOR
LYEL
Profitability
|
Metric
|
GRTX
|
VOR
|
LYEL
|
|---|---|---|---|
Return on Assets (Normalized) | −118.74% | −41.83% | −20.62% |
Return on Equity (Normalized) | — | −51.69% | −23.35% |
Return on Invested Capital (Normalized) | — | −47.03% | −24.46% |
Return on Assets
GRTX
VOR
LYEL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gqmwszxl | Sgpd | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dtbcgfq | Lhfjdj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Smqwdtxx | Mfmkcs | $98.1 Bil | |
MRNA
| Moderna Inc | Tbgzwntd | Mqfr | $39.1 Bil | |
ARGX
| argenx SE ADR | Fnmhxrzwp | Zvvp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Rjrfspwkc | Hnmpm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xzxnydjxw | Krhqx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yhgjylcl | Fqfpz | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bhpphqtd | Rdtqncw | $12.5 Bil | |
INCY
| Incyte Corp | Dncndmh | Ysmnsx | $11.9 Bil |